Clinical Trials Network, Ohio Valley Node

描述（由申请人提供）： 四年前，俄亥俄州山谷节点（OVN）加入了NIDA的临床试验网络（CTN），成为CTN的第二批受赠者之一。从一开始，OVN就一直是一个高效，热情和充满活力的节点，在提供科学和行政领导，与其他节点和NIDA工作人员合作，以及传播有关循证实践和CTN研究结果的信息方面表现出色。此外，OVN还在其附属于弗吉尼亚大学的区域研究和培训中心（RRTC）与其位于俄亥俄州、印第安纳州、肯塔基州和西弗吉尼亚州的六个原始（“核心”）社区治疗项目（CTP）之间建立了一种双向关系模型。 在本延续申请中，OVN建议通过在另外五个州增加九个额外的“协议特定”CTP，扩大OVN在网络中的中西部和阿巴拉契亚地区的存在，并增加一个密西西比三角洲组成部分，以增强CTN的地理和文化多样性。这15个OVN CTP每年共治疗52，000多名患者，将为CTN研究的潜在参与者的数量和种类做出重大贡献。每个核心OVN CTP都至少参加了一项CTN临床试验和两项调查研究，所有六个将继续分享节点的管理及其研究概念和协议的制定。尽管新的方案特异性CTP将发挥更有限的作用，但他们热情地期待参与适当的临床试验，为CTN提供扩大和丰富的患者人群。 在OVN在CTN的头四年里，我们完全沉浸在它的所有活动中。我们已经提交了9个方案概念，其中5个被选择用于进一步开发; 2个已被转化为完整的方案，其中一个目前正在招募参与者。我们一直积极参与CTN的国家委员会，提供了五个委员会主席，并编写或参与了许多SOP和“指导”文件。OVN的独特贡献包括CTN范围内用于监测和报告员工培训要求和成就的系统，用于跟踪CTN临床试验进展的系统，以及用于标准化CTN节点预算组织的模板。我们对这些成就和其他成就感到满意，同时我们感到继续努力寻找有效治疗药物滥用的重要途径的紧迫性，使我们渴望继续我们已经开始的工作。

DESCRIPTION (provided by applicant): The Ohio Valley Node (OVN) joined NIDA's Clinical Trials Network (CTN) four years ago, as one of the CTN's second wave of grantees. From the very beginning, the OVN has been a highly effective, enthusiastic, and energetic node that has excelled in providing scientific and administrative leadership, in collaborating with other nodes and with NIDA staff, and in disseminating information about evidence-based practice and the results of CTN studies. Moreover, the OVN has developed a model bi-directional relationship between its University of Cincinnati-affiliated Regional Research and Training Center (RRTC) and its six original ("core") community treatment programs (CTPs), which are located in Ohio, Indiana, Kentucky, and West Virginia. In this continuation application, the OVN proposes to enhance the geographical and cultural diversity of the CTN by expanding the OVN's Midwestern and Appalachian presence in the network and adding a Mississippi Delta component, via nine additional "protocol-specific" CTPs in five additional states. The fifteen OVN CTPs, which together treat more than 52,000 patients a year, will contribute significantly to the number and variety of potential participants for CTN studies. Each of the core OVN CTPs has participated in at least one CTN clinical trial and two survey studies and all six will continue to share in the administration of the node and in its development of research concepts and protocols. Although the new protocol-specific CTPs will play a more limited role, they are looking forward with enthusiasm to participating in appropriate clinical trials, providing an expanded and enriched patient population to the CTN. During the OVN's first four years in the CTN, we have immersed ourselves fully in all of its activities. We have submitted nine protocol concepts, of which five were chosen for further development; two have been converted into full protocols, including one which is currently enrolling participants. We have been active in the national committees of the CTN, providing five committee chairs and authoring or contributing to many SOPs and "guidance" documents. Unique contributions by the OVN include a system used CTN-wide for monitoring and reporting on staff training requirements and accomplishments, a system for tracking the progress of CTN clinical trials, and a template used to standardize the organization of CTN node budgets. The sense of satisfaction we feel in these and other accomplishments, together with the urgency we feel to continue working on the important search for effective treatments for substance abuse, make us eager to continue the work we have begun.